05/12/2025
Flinders Private Leads the Way in Alzheimer’s Treatment
A major milestone for dementia care in South Australia - Flinders Private Hospital (FPH) has successfully delivered the state’s first Donanemab infusions outside of a clinical trial.
Donanemab is a Therapeutic Goods Administration (TGA)–approved disease-modifying therapy for people in the early stages of Alzheimer’s disease. Clinical studies show that for selected patients, these therapies can modestly slow cognitive and functional decline, offering meaningful extra time for patients and families.
At present, Donanemab is available in Australia via private prescription only and is not currently listed on the Pharmaceutical Benefits Scheme (PBS). Access pathways and affordability are part of an ongoing national and international discussion about equity, cost, and readiness of health systems to deliver advanced dementia therapies. We continue to advocate for fair and equitable access for all Australians.
Our multidisciplinary team at FPH is committed to delivering this therapy safely, with rigorous MRI monitoring protocols, specialist oversight, and comprehensive patient counselling.
Special thanks to our FPH team for their leadership and collaboration in bringing this important treatment option to South Australian patients.
📷 Dr Ashwin Shukla, Specialist Geriatrician